🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join us for Dr. Alana Nguyen’s exit seminar!

Fully-Automated CAR-T Bioprocessing Platform Aids Scalability There’s still a lot of room for CGT manufacturing platform improvements. To address issues, Trenchant is developing a fully-automated cell therapy manufacturing platform for CAR-T cells. hubs.li/Q035_PL40

CAR T Cell Therapy for Glioblastoma: A Review of the First Decade of Clinical Trials dlvr.it/TJSwf2 #genetherapy #celltherapy

This study demonstrated an unprecedented role of RUNX1 in regulating hematopoietic and mesenchymal fate decisions in human pluripotent stem cells-derived hematopoiesis. doi.org/10.1093/stmcls…

Another medical milestone! The first patient treated with a prime edited therapeutic shows positive clinical outcomes consistent with effective rescue of his chronic granulomatous disease (CGD), a debilitating and life-shortening primary immunodeficiency. At least 19 base editing

So proud of Bryan Le, graduate student in Graduate Group Integrative Pathobiology UC Davis, who is presenting his thesis dissertation this morning. He started with our program as a Sacramento State Bridges Masters student and has been in the Fierro & Zhao labs for his PhD work. Dr. Le will now continue on a

Take a look at the next innovations in CAR T cell immunotherapies for cancer! Enjoy reading this review by Dr. Levine (Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉) and colleagues. 👇

Thanks for highlighting the review from Dr Levine et al on CAR T published in Cytotherapy

In case you needed a smile this Tuesday: 10-month-old baby KJ, who received a bespoke gene-editing therapy after a six month scientific sprint - "graduated" from the hospital today and went HOME! YAY SCIENCE! Here's his story: wapo.st/451ZQjT

No words - only tears of joy. And bow of gratitude to Rebecca Ahrens-nicklas (CHOP) and Kiran Musunuru (Penn) and Sadik Kassim (Danaher) - our amazing partners in designing, derisking, and administering a CRISPR on demand to Baby KJ.

For readers interested in CRISPR-based therapies, this recent review covers chemical engineering of CRISPR–Cas systems for therapeutic applications nature.com/articles/s4157… rdcu.be/epryC

Biotech Webinar – June 6 @ 3PM ET T Cell Selection: A Critical Step in the CAR-T Process How do we isolate T cells—and why does it matter for access? 🔗 Register: caringcross.org/events/ #CART #CellTherapy #Biotech #HealthEquity

A few weeks ago we introduced you to KJ, who made medical history as the first patient to receive a personalized gene editing therapy. After almost a year at CHOP, KJ is now at home with his family. 🎓 Tune in to NBC's TODAY tomorrow morning to hear from his family!

Baby KJ, the world's first patient to receive personalized CRISPR gene editing therapy for a rare metabolic disease, is now home and thriving! This groundbreaking treatment offers hope for other untreatable genetic conditions. #CRISPR #GeneEditing yahoo.com/news/worlds-fi…

A small molecule K-3 promotes PDX1 expression and potentiates the differentiation of pluripotent stem cells into insulin-producing pancreatic β cells doi.org/10.1093/stmcls…

The U.S. FDA will be hosting a roundtable on cell and gene therapy, livestreaming TODAY, at 2pm-5pm BST / 9am-12pm ET, on YouTube and X. Some panelists include: Nicole Verdun (FDA), Carl June (University of Pennsylvania), Tim Hunt (Alliance for Regenerative Medicine), Catherine

Our CA CAR-T 299 clinical trial has outcome results comparable to commercial products for relapsed DLBCL. We manufacture the T Cell product for $50k and deliver fresh cells, one week vein-to- vein. #pointofcare #GMP #academicGMP

A systemically deliverable lipid-conjugated siRNA targeting DUX4 as an Facioscapulohumeral Muscular Dystrophy therapeutic dlvr.it/TLKfv0 #MTMCD

Targeting DNA damage in ageing: towards supercharging DNA repair nature.com/articles/s4157… This new Review discusses approaches to pharmacologically mitigate the adverse effects of DNA damage to prevent mutation-driven cancers and mitigate age-related degenerative diseases

There is at least some hope for those of us in the cell and gene therapy field. 🧬Hopefully this enthusiasm translates into more NIH funding for scientists in the USA. 🙏 Without funding there are no cures.